EUVIMEDEUVIMED entdecken
Crossref

Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration

Jean-Baptiste Langlois iD, Silke Brenneisen, Stephane Rodde iD, Eric Vangrevelinghe, Geoffroy Rose, Patrick Lerch, Mickael Sorge, Thomas Ullrich, Krystyna Patora-Komisarska, Jean Quancard, Patrice Larger, Lucas Gianola und 21 weitere

Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 21163-21185

DOI: 10.1021/acs.jmedchem.4c01938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.11.2024. Verfasst von Jean-Baptiste Langlois und 32 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Biomedical Research, Postfach, CH-4002 Basel, Switzerland. Hauptthemen laut MEDLINE: MAP Kinase Kinase Kinases, Osteoarthritis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a chronic and degenerative joint disease affecting more than 500 million patients worldwide with no disease-modifying treatment approved to date. Several publications report on the transforming growth factor β-activated kinase 1 (TAK1) as a potential molecular target for OA, with complementary anti-catabolic and anti-inflammatory effects. We report herein on the development of TAK1 inhibitors with physicochemical properties suitable for intra-articular injection, with the aim to achieve high drug concentration at the affected joint, while avoiding severe toxicity associated with systemic inhibition. More specifically, reducing solubility by increasing crystallinity, while maintaining moderate lipophilicity proved to be a good compromise to ensure high and sustained free drug exposures in the joint. Furthermore, structure-based design allowed for an improvement of selectivity versus interleukin-1 receptor-associated kinases 1 and 4 (IRAK1/4). Finally, TAK-756 was discovered as a potent TAK1 inhibitor with good selectivity versus IRAK1/4 as well as excellent intra-articular pharmacokinetic properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MAP Kinase Kinase KinasesOsteoarthritisProtein Kinase InhibitorsAnimalsHumansInjections, Intra-ArticularStructure-Activity RelationshipMaleRatsMAP Kinase Kinase Kinase 7

Substanzen

MAP Kinase Kinase KinasesProtein Kinase InhibitorsMAP Kinase Kinase Kinase 7

Autor:innen und Institutionen

  • Novartis Biomedical Research, Postfach, CH-4002 Basel, Switzerland.
  • Proteros Biostructures GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried, Germany.

ORCID-Profile: Jean-Baptiste Langlois, Stephane Rodde

Zitieren

APA

Langlois, J. B., Brenneisen, S., Rodde, S., Vangrevelinghe, E., Rose, G., Lerch, P., Sorge, M., Ullrich, T., Patora-Komisarska, K., Quancard, J., Larger, P., Gianola, L., Textor, C., Chenal, G., Rubic-Schneider, T., Simkova, K., Masmanidou, O., Scheufler, C., Lammens, A., …, & Minetti, G. C. (2024). Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration. Journal of Medicinal Chemistry, 67(23), 21163-21185. https://doi.org/10.1021/acs.jmedchem.4c01938

Vancouver

Langlois JB, Brenneisen S, Rodde S, Vangrevelinghe E, Rose G, Lerch P, et al. Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration. Journal of Medicinal Chemistry. 2024;67(23):21163-21185. doi:10.1021/acs.jmedchem.4c01938

BibTeX
@article{Langlois2024,
  author = {Langlois, Jean-Baptiste and Brenneisen, Silke and Rodde, Stephane and Vangrevelinghe, Eric and Rose, Geoffroy and Lerch, Patrick and Sorge, Mickael and Ullrich, Thomas and Patora-Komisarska, Krystyna and Quancard, Jean and Larger, Patrice and Gianola, Lucas and Textor, Claudia and Chenal, Gaelle and Rubic-Schneider, Tina and Simkova, Katerina and Masmanidou, Olga and Scheufler, Clemens and Lammens, Alfred and Bouzan, Anais and Demirci, Sabrina and Flotte, Ludivine and Rivet, Helene and Hartmann, Lilian and Guezel, Danyel and Flueckiger, Manuela and Schilb, Alain and Schuepbach, Edi and Kettle, Rachel and Jacobi, Carsten and Pearson, David and Richards, Peter J and Minetti, Giulia C},
  title = {Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {23},
  pages = {21163--21185},
  doi = {10.1021/acs.jmedchem.4c01938}
}
Kostenlos starten →